MX2024005656A - Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos. - Google Patents

Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.

Info

Publication number
MX2024005656A
MX2024005656A MX2024005656A MX2024005656A MX2024005656A MX 2024005656 A MX2024005656 A MX 2024005656A MX 2024005656 A MX2024005656 A MX 2024005656A MX 2024005656 A MX2024005656 A MX 2024005656A MX 2024005656 A MX2024005656 A MX 2024005656A
Authority
MX
Mexico
Prior art keywords
methods
protein tyrosine
tyrosine phosphatase
phosphatase inhibitors
agents
Prior art date
Application number
MX2024005656A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Bogdan
Jennifer M Frost
Philip R Kym
Zhaoming Xiong
Christos Economou
Spencer O Scholz
Original Assignee
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc filed Critical Calico Life Sciences Llc
Publication of MX2024005656A publication Critical patent/MX2024005656A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2024005656A 2021-11-11 2022-11-10 Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos. MX2024005656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163278336P 2021-11-11 2021-11-11
PCT/US2022/049581 WO2023086495A1 (en) 2021-11-11 2022-11-10 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2024005656A true MX2024005656A (es) 2024-08-06

Family

ID=84887566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005656A MX2024005656A (es) 2021-11-11 2022-11-10 Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.

Country Status (8)

Country Link
US (1) US20250042894A1 (https=)
EP (1) EP4430039A1 (https=)
JP (1) JP2024543451A (https=)
CN (1) CN118556055A (https=)
AU (1) AU2022386164A1 (https=)
CA (1) CA3236853A1 (https=)
MX (1) MX2024005656A (https=)
WO (1) WO2023086495A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
BR112020026086A2 (pt) * 2018-06-21 2021-03-23 Calico Life Sciences Llc inibidores da proteína tirosina fosfatase e métodos de uso destes
IL286373B2 (en) * 2019-03-14 2026-03-01 Calico Life Sciences Llc Protein tyrosine phosphate inhibitor compounds and uses thereof
CA3162069A1 (en) * 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
US20250042894A1 (en) 2025-02-06
AU2022386164A1 (en) 2024-05-23
CA3236853A1 (en) 2023-05-19
EP4430039A1 (en) 2024-09-18
WO2023086495A1 (en) 2023-05-19
JP2024543451A (ja) 2024-11-21
CN118556055A (zh) 2024-08-27

Similar Documents

Publication Publication Date Title
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CL2021001722A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
CL2020002405A1 (es) Inhibidores de kras g12c y métodos para su uso (divisional de la solicitud no. 201903394)
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
CL2021001721A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
CO2022008091A2 (es) Inhibidores de kras g12c
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
CO2022004595A2 (es) Aminas bicíclicas como inhibidoras de la cdk2
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
CO2018011064A2 (es) Inhibidores de bromodominios
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
CO2022000481A2 (es) Inhibidores de enzimas
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
CL2023002362A1 (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.
MX2024005658A (es) Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
CO2022000266A2 (es) Inhibidores de enzimas
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
CY1124751T1 (el) Συνδυαστικες αγωγες οι οποιες περιλαμβανουν χορηγηση 1η-πυραζολο[4,3-b]πυριδινων
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
MX2024005656A (es) Inhibidores de proteina tirosina fosfatasa y metodos de uso de estos.
AR131101A1 (es) Heteroarilfluoroalquenos como inhibidores de dgk
CL2025003313A1 (es) Compuestos derivados de feniloxazolona sustituida.
CO2025016192A2 (es) Moléculas y métodos de uso de estas
CL2024001524A1 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno